76
|
Okuyama H, Ikeda M, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Yamaguchi K, Murohisa G, Shioji K, Ishii H, Mizuno N, Kojima M, Yamanaka T. A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy293.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
77
|
Mitsunaga S, Takada M, Nishikawa S, Imaizumi A, Ishii M, Ikeda M. Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
78
|
Takahashi H, Morizane C, Nomura S, Okano N, Tsuda M, Mizuno N, Satake H, Tsuji K, Shioji K, Ishii H, Yasui K, Miyakawa H, Ishiguro A, Ogura T, Ueno M, Ikeda A, Terashima T, Ikeda M, Okusaka T, Furuse J. Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
79
|
Ducreux M, Cheng AL, Qin S, Zhu A, Ikeda M, Kim TY, Xu DZ, Verret W, Liu J, Finn R, Galle P. Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
80
|
Finn R, Kudo M, Cheng AL, Wyrwicz L, Ngan R, Blanc J, Baron A, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus C, Funahashi Y, Evans T. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.057] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
81
|
Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Predictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
82
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.140] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
83
|
Cheng AL, Yen CJ, Okusaka T, Ikeda M, Hsu CH, Wu SY, Morizane C, Hashimoto Y, Ueshima K, Ohtomo T, Tanaka T, Kudo M. A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.080] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
84
|
Nakamura T, Ikeda M, Shibata S, Kon Y, Konuma K, Sanada T, Gonda H, Suto Y, Kobayashi K, Tamura H, Kobayashi M, Hasegawa A, Amagasa Y, Suzuki A, Fukuda M, Aoyagi C, Matsuura N, Kawashima Y, Shimura M, Takita N. Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
85
|
Li Z, Abe K, Bronner C, Hayato Y, Ikeda M, Iyogi K, Kameda J, Kato Y, Kishimoto Y, Marti L, Miura M, Moriyama S, Nakahata M, Nakajima Y, Nakano Y, Nakayama S, Orii A, Pronost G, Sekiya H, Shiozawa M, Sonoda Y, Takeda A, Takenaka A, Tanaka H, Tasaka S, Tomura T, Akutsu R, Kajita T, Nishimura Y, Okumura K, Tsui K, Fernandez P, Labarga L, Blaszczyk F, Gustafson J, Kachulis C, Kearns E, Raaf J, Stone J, Sulak L, Berkman S, Tobayama S, Elnimr M, Kropp W, Locke S, Mine S, Weatherly P, Smy M, Sobel H, Takhistov V, Ganezer K, Hill J, Kim J, Lim I, Park R, Himmel A, O’Sullivan E, Scholberg K, Walter C, Ishizuka T, Nakamura T, Jang J, Choi K, Learned J, Matsuno S, Smith S, Amey J, Litchfield R, Ma W, Uchida Y, Wascko M, Cao S, Friend M, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Abe KE, Hasegawa M, Suzuki A, Takeuchi Y, Yano T, Hayashino T, Hiraki T, Hirota S, Huang K, Jiang M, Mori M, Nakamura KE, Nakaya T, Patel N, Wendell R, Anthony L, McCauley N, Pritchard A, Fukuda Y, Itow Y, Murase M, Muto F, Mijakowski P, Frankiewicz K, Jung C, Li X, Palomino J, Santucci G, Vilela C, Wilking M, Yanagisawa C, Yang G, Ito S, Fukuda D, Ishino H, Kibayashi A, Koshio Y, Nagata H, Sakuda M, Xu C, Kuno Y, Wark D, Di Lodovico F, Richards B, Sedgwick S, Tacik R, Kim S, Cole A, Thompson L, Okazawa H, Choi Y, Ito K, Nishijima K, Koshiba M, Suda Y, Yokoyama M, Calland R, Hartz M, Martens K, Murdoch M, Quilain B, Simpson C, Suzuki Y, Vagins M, Hamabe D, Kuze M, Okajima Y, Yoshida T, Ishitsuka M, Martin J, Nantais C, Tanaka H, Towstego T, Konaka A, Chen S, Wan L, Zhang Y, Minamino A, Wilkes R. Measurement of the tau neutrino cross section in atmospheric neutrino oscillations with Super-Kamiokande. Int J Clin Exp Med 2018. [DOI: 10.1103/physrevd.98.052006] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
86
|
Nakahashi T, Sakata K, Tada H, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Hayashi K, Kawashiri M, Yamagishi M. P3672Assessment of ankle-brachial index to predict in-hospital bleeding complication and optimal duration of dual antiplatelet therapy in patients with acute coronary syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
87
|
Okabe K, Matsushima S, Ikeda M, Ikeda S, Ishikita A, Tadokoro T, Ide T, Tsutsui H. P2826Teneligliptin attenuated AngII-induced cardiac hypertrophy by inhibiting Nox4-HDAC4 axis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
88
|
Ikeda S, Matsushima S, Ikeda M, Ishikita A, Tadokoro T, Ide T, Tsutsui H. P5694L-type calcium channel blocker attenuates doxorubicine-induced cardiomyopathy by inhibiting CaMKII-NF-kB axis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
89
|
Urushihara T, Sumimoto R, Sumimoto K, Jamieson NV, Ikeda M, Ito H, Hong HQ, Fukuda Y, Dohi K. Prolonged rat pancreas preservation using a solution with the combination of histidine and lactobionate. Transpl Int 2018. [DOI: 10.1111/tri.1992.5.s1.336] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
90
|
Sasaki M, Imaoka H, Kan M, Suzuki Y, Kimura G, Umemoto K, Watanabe K, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Ikeda M. Safety of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients presenting with hyperbilirubinemia secondary to bile duct obstruction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
91
|
Mikami M, Tanabe K, Matsuo K, Ikeda M, Miyazawa M, Miyazawa M, Hayashi M, Machida H, Shida M, Roman L, Hirasawa T. Comprehensive serum glycopeptide spectra analysis might be a new tool for the early detection of ovarian cancer. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
92
|
Kachulis C, Abe K, Bronner C, Hayato Y, Ikeda M, Iyogi K, Kameda J, Kato Y, Kishimoto Y, Marti L, Miura M, Moriyama S, Nakahata M, Nakano Y, Nakayama S, Okajima Y, Orii A, Pronost G, Sekiya H, Shiozawa M, Sonoda Y, Takeda A, Takenaka A, Tanaka H, Tasaka S, Tomura T, Akutsu R, Kajita T, Kaneyuki K, Nishimura Y, Okumura K, Tsui KM, Labarga L, Fernandez P, Blaszczyk FDM, Gustafson J, Kearns E, Raaf JL, Stone JL, Sulak LR, Berkman S, Tobayama S, Goldhaber M, Elnimr M, Kropp WR, Mine S, Locke S, Weatherly P, Smy MB, Sobel HW, Takhistov V, Ganezer KS, Hill J, Kim JY, Lim IT, Park RG, Himmel A, Li Z, O'Sullivan E, Scholberg K, Walter CW, Ishizuka T, Nakamura T, Jang JS, Choi K, Learned JG, Matsuno S, Smith SN, Amey J, Litchfield RP, Ma WY, Uchida Y, Wascko MO, Cao S, Friend M, Hasegawa T, Ishida T, Ishii T, Kobayashi T, Nakadaira T, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Abe KE, Hasegawa M, Suzuki AT, Takeuchi Y, Yano T, Hayashino T, Hiraki T, Hirota S, Huang K, Jiang M, Nakamura KE, Nakaya T, Quilain B, Patel ND, Wendell RA, Anthony LHV, McCauley N, Pritchard A, Fukuda Y, Itow Y, Murase M, Muto F, Mijakowski P, Frankiewicz K, Jung CK, Li X, Palomino JL, Santucci G, Vilela C, Wilking MJ, Yanagisawa C, Ito S, Fukuda D, Ishino H, Kibayashi A, Koshio Y, Nagata H, Sakuda M, Xu C, Kuno Y, Wark D, Di Lodovico F, Richards B, Tacik R, Kim SB, Cole A, Thompson L, Okazawa H, Choi Y, Ito K, Nishijima K, Koshiba M, Totsuka Y, Suda Y, Yokoyama M, Calland RG, Hartz M, Martens K, Simpson C, Suzuki Y, Vagins MR, Hamabe D, Kuze M, Yoshida T, Ishitsuka M, Martin JF, Nantais CM, Tanaka HA, Konaka A, Chen S, Wan L, Zhang Y, Wilkes RJ, Minamino A. Search for Boosted Dark Matter Interacting with Electrons in Super-Kamiokande. PHYSICAL REVIEW LETTERS 2018; 120:221301. [PMID: 29906152 DOI: 10.1103/physrevlett.120.221301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 03/23/2018] [Indexed: 06/08/2023]
Abstract
A search for boosted dark matter using 161.9 kt yr of Super-Kamiokande IV data is presented. We search for an excess of elastically scattered electrons above the atmospheric neutrino background, with a visible energy between 100 MeV and 1 TeV, pointing back to the Galactic center or the Sun. No such excess is observed. Limits on boosted dark matter event rates in multiple angular cones around the Galactic center and Sun are calculated. Limits are also calculated for a baseline model of boosted dark matter produced from cold dark matter annihilation or decay. This is the first experimental search for boosted dark matter from the Galactic center or the Sun interacting in a terrestrial detector.
Collapse
|
93
|
Shimazawa R, Ikeda M. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels. J Clin Pharm Ther 2018; 43:500-506. [DOI: 10.1111/jcpt.12692] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 03/26/2018] [Indexed: 01/02/2023]
|
94
|
Yang SB, Ahn JK, Akazawa Y, Aoki K, Chiga N, Ekawa H, Evtoukhovitch P, Feliciello A, Fujita M, Hasegawa S, Hayakawa S, Hayakawa T, Honda R, Hosomi K, Hwang SH, Ichige N, Ichikawa Y, Ikeda M, Imai K, Ishimoto S, Kanatsuki S, Kim SH, Kinbara S, Kobayashi K, Koike T, Lee JY, Miwa K, Moon TJ, Nagae T, Nakada Y, Nakagawa M, Ogura Y, Sakaguchi A, Sako H, Sasaki Y, Sato S, Shirotori K, Sugimura H, Suto S, Suzuki S, Takahashi T, Tamura H, Tanida K, Togawa Y, Tsamalaidze Z, Ukai M, Wang TF, Yamamoto TO. First Determination of the Level Structure of an sd-Shell Hypernucleus, _{Λ}^{19}F. PHYSICAL REVIEW LETTERS 2018; 120:132505. [PMID: 29694189 DOI: 10.1103/physrevlett.120.132505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 02/15/2018] [Indexed: 06/08/2023]
Abstract
We report on the first observation of γ rays emitted from an sd-shell hypernucleus, _{Λ}^{19}F. The energy spacing between the ground state doublet, 1/2^{+} and 3/2^{+} states, of _{Λ}^{19}F is determined to be 315.5±0.4(stat)_{-0.5}^{+0.6}(syst) keV by measuring the γ-ray energy of the M1(3/2^{+}→1/2^{+}) transition. In addition, three γ-ray peaks are observed and assigned as E2(5/2^{+}→1/2^{+}), E1(1/2^{-}→1/2^{+}), and E1(1/2^{-}→3/2^{+}) transitions. The excitation energies of the 5/2^{+} and 1/2^{-} states are determined to be 895.2±0.3(stat)±0.5(syst) and 1265.6±1.2(stat)_{-0.5}^{+0.7}(syst) keV, respectively. It is found that the ground state doublet spacing is well described by theoretical models based on existing s- and p-shell hypernuclear data.
Collapse
|
95
|
Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanii H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry 2018; 23:639-647. [PMID: 28115744 PMCID: PMC5822448 DOI: 10.1038/mp.2016.259] [Citation(s) in RCA: 119] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 11/29/2016] [Accepted: 12/13/2016] [Indexed: 11/09/2022]
Abstract
Genome-wide association studies (GWASs) have identified several susceptibility loci for bipolar disorder (BD) and shown that the genetic architecture of BD can be explained by polygenicity, with numerous variants contributing to BD. In the present GWAS (Phase I/II), which included 2964 BD and 61 887 control subjects from the Japanese population, we detected a novel susceptibility locus at 11q12.2 (rs28456, P=6.4 × 10-9), a region known to contain regulatory genes for plasma lipid levels (FADS1/2/3). A subsequent meta-analysis of Phase I/II and the Psychiatric GWAS Consortium for BD (PGC-BD) identified another novel BD gene, NFIX (Pbest=5.8 × 10-10), and supported three regions previously implicated in BD susceptibility: MAD1L1 (Pbest=1.9 × 10-9), TRANK1 (Pbest=2.1 × 10-9) and ODZ4 (Pbest=3.3 × 10-9). Polygenicity of BD within Japanese and trans-European-Japanese populations was assessed with risk profile score analysis. We detected higher scores in BD cases both within (Phase I/II) and across populations (Phase I/II and PGC-BD). These were defined by (1) Phase II as discovery and Phase I as target, or vice versa (for 'within Japanese comparisons', Pbest~10-29, R2~2%), and (2) European PGC-BD as discovery and Japanese BD (Phase I/II) as target (for 'trans-European-Japanese comparison,' Pbest~10-13, R2~0.27%). This 'trans population' effect was supported by estimation of the genetic correlation using the effect size based on each population (liability estimates~0.7). These results indicate that (1) two novel and three previously implicated loci are significantly associated with BD and that (2) BD 'risk' effect are shared between Japanese and European populations.
Collapse
|
96
|
Kikkawa T, Yorifuji T, Fujii Y, Yashiro M, Okada A, Ikeda M, Doi H, Tsukahara H. Birth order and paediatric allergic disease: A nationwide longitudinal survey. Clin Exp Allergy 2018; 48:577-585. [PMID: 29368358 DOI: 10.1111/cea.13100] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 11/24/2017] [Accepted: 12/21/2017] [Indexed: 01/14/2023]
Abstract
BACKGROUND Environmental factors seem to be related to the incidence of allergic disease. Children with a later birth order are often exposed to environments, where pathogens and endotoxins can be found, and thus have a higher risk of developing infectious diseases. Therefore, birth order is regarded as an indicator that reflects post-natal environment. However, longitudinal studies are limited on this subject. This study sought to elucidate the relationships between birth order and allergic disease. METHODS From a nationwide longitudinal study that followed children born in 2001 (n = 47 015), we selected doctors' visits for 3 types of allergic disease-bronchial asthma, food allergy and atopic dermatitis-from infancy to 12 years of age and conducted binomial log-linear regression analysis to evaluate the associations between birth order and these diseases. We adjusted for the child and parental factors and estimated risk ratio (RR) and 95% confidence interval (CI) for each outcome. RESULTS The associations between birth order and bronchial asthma were diverse; later birth order increased the risk in early childhood, but decreased the risks during school age. For example, the adjusted RR comparing third-born or higher and first-born children was 1.19 (95% CI, 1.05-1.35) between 30 and 42 months of age, but was 0.76 (95% CI, 0.65-0.89) between 10 and 11 years. Later birth order was generally protective for food allergy but increased the risk of atopic dermatitis. CONCLUSION The influence of birth order depended on the type of allergic disease and the childhood period. Childhood is unique in terms of physical and immunological development, and the immune response to the post-natal environment in childhood appears to be heterogeneous.
Collapse
|
97
|
Yamaguchi M, Nakayama T, Yoshinami T, Ikeda M, Iwamoto M, Komoike Y, Takashima T, Tsurutani J, Yoshidome K, Yamada T, Morita S, Masuda N. Abstract OT2-06-02: A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The combination therapy of Bevacizumab (B) and Paclitaxel (P) has proved to prolong progression free survival (PFS) in E2100 and MERiDiAN study for advanced and metastatic breast cancer(AMBC). Because of its longer PFS, developing optimal therapeutic strategy of B+P to improve survival, including management of toxicity is crucial. From the International Consensus Conference for Advanced Breast Cancer, most experts agreed the maintenance endocrine therapy after effective induction chemotherapy in AMBC. In KBCSG-TR 1214 study, we planned to examine the following clinical questions. 1. As a maintenance therapy, which is more effective either endocrine therapy alone (E) or endocrine therapy with capecitabine (E+C)? 2. Can maintenance therapy reduce toxicity of B+P and restore patient's QOL.? 3. How effective is B+P re-challenge after failure of maintenance therapy?
Methods: KBCSG-TR 1214 study is multicenter open-labeled randomized phase II trial for hormone receptor (HR)-positive and HER2-nagative patientswho have experienced none or one prior chemotherapy for AMBC. Patients will receive B (10mg/kg q2w) in combination with P (90mg/m2 on day 1, 8, and 15 q4w) as an induction therapy. Patients without progression after 6 cycles of B+P will be randomized to E or E+C. Endocrine treatment has been administrated by their physician's choice. Patients in E+C will receive endocrine therapy with capecitabine 1657mg/m2 on day1 to 21 q4w. Stratification factors for randomization are menopausal status, presence of target lesion, number of prior endocrine therapies for AMBC, with or without 1st line chemotherapy for AMBC. After progression of maintenance therapy (E or E+C), B+P will be started again as a re-challenge therapy. Primary end point is PFS of maintenance therapy. Secondary end points include time to failure of strategy from randomization, efficacy of re-challenge therapy, overall survival and safety of induction therapy. Translational research is also planned. VEGF, angiopoetin-1, and apelin in plasma will be measured at four points (before induction therapy, at the beginning of the maintenance therapy and the re-induction therapy, and at the end of the trial). The sample size was calculated by typeIerror (1-sided) of 0.05 and 80% power to estimate median PFS of each maintenance therapy 9 months with a threshold of 6 months. The target number of patients enrolled and randomized after induction therapy was 120 and 90, respectively.
Enrollment has been completed with 116 patients as of April, 2016 and 90 patients had been successful to shift to the maintenance phase with randomization. The last patient had been randomized on October, 2016. The first analysis will be planned during the second quarter of 2018 (UMIN000008662).
Citation Format: Yamaguchi M, Nakayama T, Yoshinami T, Ikeda M, Iwamoto M, Komoike Y, Takashima T, Tsurutani J, Yoshidome K, Yamada T, Morita S, Masuda N. A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-06-02.
Collapse
|
98
|
Nishimura R, Yamamoto Y, Narui K, Kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S, Iwase H. Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: After the failure of a non-steroidal aromatase inhibitor (nsAI) for postmenopausal patients with advanced/metastatic breast cancer (BC), it is unclear which of the various kinds of endocrine monotherapy is the most appropriate. In a previous report it was found that toremifene 120 mg (TOR 120), a selective estrogen receptor modulator (SREM), was superior to steroidal AI in terms of progression-free survival after ns-AI in the Hi-FAIR ex trial. A phase II randomized trial of TOR 120 versus fulvestrant 500 mg (FUL 500), a selective estrogen receptor down regulator (SERD), was also conducted to select the most promising endocrine monotherapy after ns-AI in advanced/metastatic BC(Study registry number: UMIN000010087).
Patients and Methods: Postmenopausal women (n=106) with advanced/metastatic hormone-receptor positive BC from October 2011 to September 2014 were enrolled in this study. Fifty-three of the patients were randomly assigned to the TOR 120 (120 mg daily p.) group and 53 of the patients were randomly assigned to the FUL 500 group. In the FUL 500 group they were administered 500 mg of fulvestrant intramuscularly (im) on day 0, then 500 mg im on days 14 and 28 and every 28 days thereafter). If treatment failure occurred in either of the randomly assigned groups the patients were then removed and treated accordingly. A full analysis set was targeted for all cases that received the protocol treatment even once (TOR 120 (n=53) and FUL 500 (n=52)). The primary end point was the clinical benefit rate (CBR). The secondary end points were the objective response rate (ORR), progression-free survival (PFS), time to chemotherapy (TTCT), overall survival (OS), toxicity, and CBR, ORR and PFS after crossover of non-assigned treatment.
Results: A median follow up period of 30 months revealed that the CBR of FUL 500 (57.7%) tended to be superior to the CBR of TOR 120 (45.3%), the odds ratio (OR) was 1.70 (95% CI 0.74–3.62), and the median PFS was 7.8 months in the FUL 500 group and 5.8 months in the TOR 120 group. Moreover the hazard ratio (HR) was 0.79 (95% CI 0.52–1.21). However, there was no difference between the two groups in terms of ORR (17.7% and 15.1%, respectively), TTCT (13.3 months vs. 17.7 months, HR = 0.94 (95%CI 0.57 – 1.53)), and OS (33.4 months vs. not reached HR 1.29; 95% CI 0.80–2.09). At the cross-over phase, 33 and 24 patients after failure of assigned treatment were treated with FUL 500 and TOR 120, respectively. The CBR and PFS of FUL 500 after TOR 120 was better than that of TOR 120 after FUL 500 (CBR; 42.4% vs. 20.8%, OR = 0.33, 95%CI 0.09 – 1.11, median PFS; 6.2 months vs. 3.4 months; HR = 1.95, 95%CI 1.08–3.51). No difference between the two groups was observed in PFS from randomization to the end of the crossover phase. Moreover, there were few severe adverse events in either of the two groups.
Conclusions: FUL 500 used as a subsequent endocrine therapy for advanced/metastatic BC patients who failed ns-AI could potentially be more effective than TOR 120. However, the efficacy of SERM after failure of FUL 500 may be limited.
Citation Format: Nishimura R, Yamamoto Y, Narui K, Kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S, Iwase H. A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-02.
Collapse
|
99
|
Itoh S, Ishigaki T, Yamauchi K, Ikeda M. Application of Resampling Techniques to the Statistical Analysis of the Brier Score. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1634163] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Abstract:We investigated the application of resampling techniques to the statistical analysis of the Brier score (B), and extended them to the statistical comparison of two Bs derived from the same set of patients. The re-sampling techniques are helpful in the statistical analysis of B, and there are almost no differences between the jackknife method and the bootstrap method in this analysis. Thus, we believe that B should be used more often as an index to evaluate probabilistic judgments in the case in which the data sets for the assessment are “degenerate” as the “receiver operating characteristic data sets.”
Collapse
|
100
|
Saad A, Inoue G, Nikaido T, Ikeda M, Burrow MF, Tagami J. Microtensile Bond Strength of Resin-Modified Glass Ionomer Cement to Sound and Artificial Caries–Affected Root Dentin With Different Conditioning. Oper Dent 2017; 42:626-635. [DOI: 10.2341/16-375-l] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
SUMMARY
In this laboratory study, the microtensile bond strengths (μTBS) of resin-modified glass ionomer cement (RM-GIC) to sound and artificial caries–affected bovine root dentin (ACAD) using three different conditioning agents were evaluated after 24 hours and three months. The fractured interface was examined with a scanning electron microscope (SEM). Specimens were created on bovine root dentin that was embedded in epoxy resin. For the ACAD specimens, artificial carious lesions were created. The RM-GIC (Fuji II LC) was applied either directly (no treatment), after application of self conditioner, cavity conditioner, or 17% ethylenediamine tetraacetic acid (EDTA) applied for 60 seconds, on sound dentin and ACAD, then light cured. They were stored in artificial saliva for 24 hours or three months. Following this, the specimens were cut into sticks for the μTBS test, and the failure mode of the debonded specimens was examined by using SEM. Pretest failures were excluded from the statistical analysis of the μTBS values because of their high incidence in some groups. Results showed that the μTBS values were significantly affected by the dentin substrate as well as the conditioning agent. Self conditioner provided the highest and most stable μTBS values, while cavity conditioner showed stable μTBS values on sound dentin. Both self conditioner and cavity conditioner had significantly higher μTBS values than the no treatment groups. EDTA conditioning reduced the μTBS after three months to sound dentin, while it showed 100% pretest failure with ACAD for both storage periods.
Collapse
|